Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB) : final overall survival analysis": [Annals of Oncology 33 (2022) 321-329
| Errataetall: |
ErratumFor: Ann Oncol. 2022 Mar;33(3):321-329. - PMID 34954044 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 34(2023), 7 vom: 16. Juli, Seite 630 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Curigliano, G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.06.2023 published: Print-Electronic ErratumFor: Ann Oncol. 2022 Mar;33(3):321-329. - PMID 34954044 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2022.12.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350757933 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350757933 | ||
| 003 | DE-627 | ||
| 005 | 20231226045722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2022.12.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350757933 | ||
| 035 | |a (NLM)36564285 | ||
| 035 | |a (PII)S0923-7534(22)04773-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB) |b final overall survival analysis": [Annals of Oncology 33 (2022) 321-329 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumFor: Ann Oncol. 2022 Mar;33(3):321-329. - PMID 34954044 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Mueller, V |e verfasserin |4 aut | |
| 700 | 1 | |a Borges, V |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, E |e verfasserin |4 aut | |
| 700 | 1 | |a Hurvitz, S |e verfasserin |4 aut | |
| 700 | 1 | |a Loi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, R |e verfasserin |4 aut | |
| 700 | 1 | |a Okines, A |e verfasserin |4 aut | |
| 700 | 1 | |a Paplomata, E |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, D |e verfasserin |4 aut | |
| 700 | 1 | |a Carey, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Gelmon, K |e verfasserin |4 aut | |
| 700 | 1 | |a Hortobagyi, G N |e verfasserin |4 aut | |
| 700 | 1 | |a Krop, I |e verfasserin |4 aut | |
| 700 | 1 | |a Loibl, S |e verfasserin |4 aut | |
| 700 | 1 | |a Pegram, M |e verfasserin |4 aut | |
| 700 | 1 | |a Slamon, D |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, J |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, W |e verfasserin |4 aut | |
| 700 | 1 | |a Winer, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 34(2023), 7 vom: 16. Juli, Seite 630 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:7 |g day:16 |g month:07 |g pages:630 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2022.12.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 7 |b 16 |c 07 |h 630 | ||